|
PIGW expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.49160000018078E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.34650000050263E-07 |
| Normal-vs-Stage2 |
6.543900E-02 |
| Normal-vs-Stage3 |
2.73740000000799E-07 |
| Normal-vs-Stage4 |
3.0162999997696E-07 |
| Stage1-vs-Stage2 |
2.315700E-02 |
| Stage1-vs-Stage3 |
1.519160E-01 |
| Stage1-vs-Stage4 |
4.770000E-02 |
| Stage2-vs-Stage3 |
4.503000E-03 |
| Stage2-vs-Stage4 |
1.678150E-03 |
| Stage3-vs-Stage4 |
4.463400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.35280000219163E-08 |
| Normal-vs-AfricanAmerican |
1.953580E-04 |
| Normal-vs-Asian |
6.359600E-03 |
| Caucasian-vs-AfricanAmerican |
4.094400E-01 |
| Caucasian-vs-Asian |
1.890600E-01 |
| AfricanAmerican-vs-Asian |
1.553440E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6582999995407E-07 |
| Normal-vs-Female |
1.08129999998319E-06 |
| Male-vs-Female |
2.847800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.29189999995305E-06 |
| Normal-vs-Age(41-60Yrs) |
7.98649999467216E-08 |
| Normal-vs-Age(61-80Yrs) |
6.03989999999888E-05 |
| Normal-vs-Age(81-100Yrs) |
5.563000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.924620E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.331600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.254420E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.149200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.850500E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.408790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.164400E-02 |
| Classical-VS-Follicular |
4.096200E-01 |
| Classical-VS-Other |
7.530300E-02 |
| Classical-VS-Normal |
1.60619999999279E-05 |
| Tall-VS-Follicular |
1.987030E-01 |
| Tall-VS-Other |
4.539400E-01 |
| Tall-VS-Normal |
1.56137999999251E-05 |
| Follicular-VS-Other |
1.762580E-01 |
| Follicular-VS-Normal |
6.27530000000265E-05 |
| Other-VS-Normal |
1.562960E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.88839999999413E-05 |
| Normal-vs-N1 |
3.65970000000271E-05 |
| N0-vs-N1 |
3.175200E-01 |
|
|
